Highlights • Survival outcomes for patients with stage IV UC and distant metastases remain poor. • Platinum-based chemotherapy remains the standard of care for untreated, advanced UC. • First-line treatment options that provide a long-term survival benefit are needed. • New data supports improved survival outcomes with immune checkpoint inhibitors.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile